First Subject Dosed with FTX-101. This study marks the beginning of a journey toward a potential treatment for chronic optic neuropathy, a condition that severely impacts vision due to the demyelination of the optic nerve.
Find Therapeutics today announced the closing of a $8.1 million (CAD$11 million) convertible note financing led by Investissement Québec with participation from current investors